

Henry Lik Yuen Chan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6123369/henry-lik-yuen-chan-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

456 papers	33,075 citations	93 h-index	167 g-index
488 ext. papers	39,357 ext. citations	7 avg, IF	7.06 L-index

#	Paper	IF	Citations
456	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016 , 10, 1-98	8.8	1288
455	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196
454	Hepatitis B virus infection. <i>Lancet, The</i> , 2014 , 384, 2053-63	40	930
453	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 454-62	11.2	790
452	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012 , 6, 531-61	8.8	768
451	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015 , 373, 2599-607	59.2	758
450	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 383-403	18.8	702
449	Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. <i>Journal of Clinical Oncology</i> , 2009 , 27, 605-11	2.2	507
448	Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. <i>New England Journal of Medicine</i> , 2005 , 352, 238-44	59.2	447
447	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010 , 59, 969-74	19.2	431
446	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology, The</i> , 2011 , 12, 568-74	21.7	427
445	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1317-25	11.5	392
444	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. <i>Gut</i> , 2004 , 53, 1494-8	19.2	366
443	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1660-5	2.2	336
442	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012 , 61, 409-15	19.2	328
441	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. <i>Hepatology</i> , 2013 , 58, 1537-47	11.2	321
440	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 36-44	2.4	307

439	Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1067-77	6.1	293
438	Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015 , 62, 956-67	13.4	285
437	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016 , 65, 1359-68	19.2	271
436	Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 1462-8	6.9	271
435	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 18761-8	11.5	267
434	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 196-206	18.8	259
433	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 254-69	6.1	249
432	Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1862-71	0.7	244
431	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 177-82	2.2	242
430	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet, The</i> , 2007 , 369, 1621-6	4.0	239
429	Eradication of <i>Helicobacter pylori</i> and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. <i>Lancet, The</i> , 2002 , 359, 9-13	4.0	239
428	Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , 2011 , 55, 1121-31	13.4	237
427	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 185-195	18.8	237
426	Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. <i>Hepatology</i> , 1999 , 29, 976-84	11.2	231
425	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016 , 150, 134-144.e10	13.3	219
424	Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. <i>Radiology</i> , 2013 , 269, 910-8	20.5	218
423	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	216
422	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 70-85	4	211

421	A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. <i>Annals of Internal Medicine</i> , 2005 , 142, 240-50 ⁸	207
420	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. <i>PLoS ONE</i> , 2013 , 8, e62885	3.7 205
419	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011 , 60, 1721-7	19.2 205
418	Viral-human chimeric transcript predisposes risk to liver cancer development and progression. <i>Cancer Cell</i> , 2014 , 25, 335-49	24.3 199
417	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , 2010 , 52, 1232-41	11.2 192
416	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017 , 66, 398-411	13.4 191
415	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013 , 12, 256-262	3.1 187
414	Hepatocellular carcinoma and hepatitis B virus. <i>Seminars in Liver Disease</i> , 2006 , 26, 153-61	7.3 187
413	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , 2012 , 56, 833-9	13.4 184
412	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. <i>Journal of Hepatology</i> , 2013 , 59, 536-42	13.4 183
411	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011 , 60, 829-36	19.2 183
410	Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. <i>Gastroenterology</i> , 2005 , 128, 1890-7	13.3 182
409	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018 , 68, 672-681	13.4 180
408	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014 , 60, 339-45	13.4 173
407	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009 , 124, 2766-70	7.5 171
406	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009 , 58, 111-7	19.2 168
405	Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. <i>Hepatology</i> , 2000 , 31, 763-8	11.2 168
404	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1306-14; quiz 1315	0.7 164

403	Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. <i>American Journal of Gastroenterology</i> , 2005 , 100, 616-23	0.7	164
402	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013 , 58, 872-80	11.2	163
401	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4138-48	3.1	162
400	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , 2017 , 65, 54-64	11.2	160
399	Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. <i>Hepatology</i> , 2011 , 54, 1591-9	11.2	153
398	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , 2017 , 7, 45846	4.9	152
397	Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1154-61	6.9	152
396	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012 , 56, 533-40	10.4	151
395	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015 , 64, 667-72	19.2	148
394	Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. <i>Annals of Internal Medicine</i> , 2007 , 147, 745-54	8	148
393	Fatty pancreas, insulin resistance, and Ectel function: a population study using fat-water magnetic resonance imaging. <i>American Journal of Gastroenterology</i> , 2014 , 109, 589-97	0.7	140
392	Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. <i>Gastroenterology</i> , 2013 , 144, 933-44	13.3	136
391	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017 , 65, 1145-1155	11.2	135
390	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , 2012 , 142, 513-520.e1	13.3	134
389	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1104-12	6.1	134
388	Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1027-35	6.9	127
387	Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. <i>Clinical Chemistry</i> , 2008 , 54, 1528-36	5.5	124
386	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2002 , 97, 406-12	0.7	123

385	Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. <i>Gastroenterology</i> , 2014 , 146, 1240-8	13.3	117
384	The changing epidemiology of liver diseases in the Asia-Pacific region. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 57-73	24.2	116
383	Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. <i>Clinical Chemistry</i> , 2005 , 51, 328-35	5.5	114
382	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011 , 54, 236-42	13.4	110
381	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 300-5	4	109
380	Efficacy of cap-assisted colonoscopy in comparison with regular colonoscopy: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , 2009 , 104, 41-6	0.7	106
379	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 848-55	4	106
378	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015 , 121, 97-108	10.8	105
377	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016 , 34, 83-90	2.2	105
376	Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015 , 62, 182-9	13.4	104
375	Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 1277-9	9.7	104
374	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 56-67	18.8	103
373	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 344-52	6.1	100
372	High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. <i>Gastroenterology</i> , 2009 , 137, 525-31	13.3	99
371	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014 , 59, 986-95	11.2	98
370	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 139-46	4	98
369	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1095-103	6.1	97
368	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018 , 69, 1349-1356	13.4	96

367	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 617-627	6.1	94
366	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020 , 158, 215-225.e6	13.3	94
365	Comparison of EUS and ERCP in the investigation with suspected biliary obstruction caused by choledocholithiasis: a randomized study. <i>Gastrointestinal Endoscopy</i> , 2008 , 67, 660-8	5.2	93
364	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008 , 28, 79-87	7.9	93
363	Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Infectious Diseases</i> , 2011 , 204, 408-14	7	91
362	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1323-31	6.1	89
361	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 667-676	4	87
360	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 387-96	6.1	87
359	Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. <i>Antiviral Therapy</i> , 2011 , 16, 1249-57	1.6	86
358	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1002-7	4	85
357	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010 , 51, 1945-53	11.2	85
356	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017 , 67, 902-908	13.4	84
355	Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. <i>Hepatology</i> , 2010 , 51, 2008-19	11.2	84
354	Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. <i>Journal of Infectious Diseases</i> , 2005 , 191, 2022-32	7	84
353	Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. <i>Modern Pathology</i> , 2004 , 17, 1169-79	9.8	83
352	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 532-9	6.1	82
351	Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1682-8	0.7	82
350	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019 , 29, 418-427	9.7	81

349	Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. <i>Annals of Surgery</i> , 2013 , 257, 922-8	7.8	81
348	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017 , 67, 577-584	13.4	80
347	Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. <i>Gastroenterology</i> , 2005 , 128, 1845-50	13.3	80
346	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1215-22	6.1	80
345	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019 , 70, 361-370	13.4	80
344	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 883-93	6.1	79
343	Factors associated with viral breakthrough in lamivudine monoprophyllaxis of hepatitis B virus recurrence after liver transplantation. <i>Journal of Medical Virology</i> , 2002 , 68, 182-7	19.7	79
342	Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. <i>Journal of Clinical Gastroenterology</i> , 2002 , 34, 569-72	3	78
341	Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 732-43	3.4	77
340	On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2011 , 16, 165-72	1.6	75
339	Histone Deacetylase HDAC8 Promotes Insulin Resistance and β -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015 , 75, 4803-16	10.1	74
338	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 447-456	6.1	73
337	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , 2019 , 156, 1392-1403.e7	13.3	73
336	Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. <i>American Journal of Gastroenterology</i> , 2008 , 103, 3071-81	0.7	73
335	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E10925-E10933	11.5	73
334	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 86-98 ⁴		71
333	A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1714-23	11.6	71
332	Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. <i>Gastrointestinal Endoscopy</i> , 2001 , 53, 438-42	5.2	71

331	Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 16-34	6.1	70
330	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1391-6	4	69
329	Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1361-6	6.9	69
328	Histological progression of non-alcoholic fatty liver disease in Chinese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 407-13	6.1	69
327	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016 , 63, 754-63	11.2	68
326	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013 , 23, 471-82	12.7	66
325	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2013 , 20, e37-46	3.4	66
324	Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1211-5	0.7	66
323	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019 , 68, 2057-2064	19.2	65
322	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
321	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021 , 70, 733-742	19.2	65
320	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1726-31	4	64
319	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005 , 41, 1357-64	11.2	64
318	Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. <i>Gastroenterology</i> , 2010 , 138, 694-704, 704.e1	13.3	63
317	Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. <i>PLoS ONE</i> , 2011 , 6, e22888	3.7	63
316	Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. <i>Disease Markers</i> , 2015 , 2015, 564057	3.2	62
315	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016 , 64, 1011-1019	13.4	61
314	Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 517-26	6.1	61

313	The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. <i>Journal of Viral Hepatitis</i> , 2002 , 9, 424-8	3.4	61
312	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015 , 62, 684-93	11.2	60
311	Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. <i>Journal of Virology</i> , 2008 , 82, 3604-11	6.6	60
310	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015 , 63, 1190-7	13.4	59
309	Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 227-33	6.9	59
308	Chronic hepatitis B in Asia-new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26 Suppl 1, 131-7	4	58
307	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , 2011 , 46, 391-400	6.9	58
306	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014 , 61, 708-9	13.4	56
305	Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. <i>Journal of Ethnopharmacology</i> , 2005 , 100, 180-6	5	56
304	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015 , 10, e0139310	3.7	56
303	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
302	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 955-61	4	55
301	How should we manage patients with non-alcoholic fatty liver disease in 2007?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 801-8	4	55
300	Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1516-23	0.7	55
299	The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1899-905	6.1	54
298	Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 914-21	4	53
297	Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1179-86	4	52
296	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017 , 65, 1840-1850	11.2	51

295	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 776-787	18.8	51
294	Hepatitis B virus reactivation associated with anti-neoplastic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 31-7	4	50
293	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1812-1823	0.7	49
292	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2017 ,	13.4	49
291	A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. <i>Journal of Hepatology</i> , 2015 , 62, 1100-11	13.4	49
290	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 1057-66	6.1	49
289	Association between anthropometric parameters and measurements of liver stiffness by transient elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 295-302.e1-3	6.9	48
288	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. <i>Journal of Medical Virology</i> , 2010 , 82, 1494-500	19.7	48
287	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2017 ,	13.4	47
286	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2018 , 32, 37-51	0.9	47
285	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018 , 64, 1239-1249	5.5	47
284	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 197-208	6.1	47
283	Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010 , 105, 132-8	0.7	47
282	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007 , 13, 1228-35	4.5	47
281	High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. <i>Clinical Chemistry</i> , 2007 , 53, 1254-63	5.5	47
280	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020 , 72, 19-31	11.2	47
279	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 731-40	6.1	46
278	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 441-453	18.8	45

277	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. <i>World Journal of Gastroenterology</i> , 2003 , 9, 2695-7	5.6	45
276	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018 , 69, 793-802	13.4	45
275	Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. <i>Gut</i> , 2014 , 63, 1793-804	19.2	44
274	Surrogate end points and long-term outcome in patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1113-20	6.9	44
273	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010 , 4, 386-95	8.8	44
272	Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2008 , 80, 591-7	19.7	44
271	Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. <i>Journal of Viral Hepatitis</i> , 2002 , 9, 229-34	3.4	44
270	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. <i>Cancer Discovery</i> , 2020 , 10, 664-673	24.4	42
269	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 730-737	6.1	42
268	Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1326-35	6.1	42
267	Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 783-90.e1	6.9	42
266	Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 45-9	6.1	42
265	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 199-208	6.1	41
264	Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. <i>Molecular and Cellular Proteomics</i> , 2009 , 8, 2582-94	7.6	41
263	Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. <i>Diabetologia</i> , 2006 , 49, 1777-84	10.3	41
262	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. <i>Liver International</i> , 2004 , 24, 611-8	7.9	41
261	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 175-182	6.1	40
260	Effect of celecoxib on experimental liver fibrosis in rat. <i>Liver International</i> , 2006 , 26, 125-36	7.9	40

259	Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 1059-68	6.1	39
258	Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1737-44	6.1	38
257	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1001-1010	6.1	37
256	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015 , 63, 1086-92	13.4	37
255	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 984-992	6.1	37
254	Multiplex detection of 60 hepatitis B virus variants by maldi-tof mass spectrometry. <i>Clinical Chemistry</i> , 2009 , 55, 1503-9	5.5	37
253	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010 , 15, 145-55	1.6	37
252	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 891-8	6.1	37
251	RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2007 , 253, 43-52	9.9	37
250	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1481-1489.e5	6.9	36
249	Liver injury is common among chronic abusers of ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1759-62.e1	6.9	36
248	Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 519-28	6.1	36
247	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2161-2171.e5	6.9	36
246	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 411-21	6.1	35
245	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1363-1369	4	34
244	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , 2011 , 65, 556-8	5.1	34
243	An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8041-7	2.2	34
242	Clinical significance of hepatic derangement in severe acute respiratory syndrome. <i>World Journal of Gastroenterology</i> , 2005 , 11, 2148-53	5.6	34

241	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patientsQ characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , 2014 , 114, 754-60	5.6	33
240	52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. <i>PLoS ONE</i> , 2013 , 8, e54279	3.7	33
239	Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. <i>Asian Journal of Surgery</i> , 2008 , 31, 41-9	1.6	33
238	COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 374, 175-80	3.4	33
237	Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. <i>Hepatology</i> , 2007 , 46, 315-23	11.2	33
236	Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. <i>Gut</i> , 2007 , 56, 991-9	19.2	33
235	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020 , 40, 581-589	7.9	33
234	Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. <i>Hepatology</i> , 2008 , 47, 473-83	11.2	32
233	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 801-811	6.1	31
232	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monophylaxis. <i>Clinical Transplantation</i> , 2004 , 18, 295-300	3.8	31
231	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , 2016 , 95, e2702	1.8	31
230	Predictors of treatment response in chronic hepatitis B. <i>Drugs</i> , 2009 , 69, 2167-77	12.1	30
229	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 538-544	18.8	29
228	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 765-773.e2	6.9	29
227	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 825-34	3.4	29
226	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1842-8	4	29
225	Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. <i>Journal of Cellular Biochemistry</i> , 2006 , 97, 795-812	4.7	29
224	Transmission of hepatitis B by human bite--confirmation by detection of virus in saliva and full genome sequencing. <i>Journal of Clinical Virology</i> , 2005 , 33, 254-6	14.5	29

223	Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 3205-8	9.7	29
222	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 802-13	6.1	28
221	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 3487-3497	4	28
220	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 116-20	4	28
219	A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2205-11	0.7	28
218	Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 251-60	6.1	28
217	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 957-966	6.1	28
216	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1278-1284	11.6	27
215	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	27
214	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1037-1048	6.1	27
213	Data mining on DNA sequences of hepatitis B virus. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2011 , 8, 428-40	3	27
212	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011 , 31, 1047-53	7.9	27
211	Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 372, 571-7	3.4	27
210	A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, S136-43	3	27
209	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, 916-928	0.7	27
208	Tenofovir Alafenamide: A Review in Chronic Hepatitis B. <i>Drugs</i> , 2017 , 77, 1017-1028	12.1	26
207	Historical epidemiology of hepatitis C virus in select countries-volume 4. <i>Journal of Viral Hepatitis</i> , 2017 , 24 Suppl 2, 8-24	3.4	26
206	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 506-514	4	26

205	Coronavirus in severe acute respiratory syndrome (SARS). <i>Trends in Molecular Medicine</i> , 2003 , 9, 323-5	11.5	26
204	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2629-33	0.7	26
203	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 72, 847-854	13.4	26
202	Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. <i>Journal of Pathology</i> , 2015 , 237, 38-49	9.4	25
201	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016 , 65, 887-8	19.2	25
200	Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014 , 60, 809-15	13.4	25
199	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016 , 17, 538-546	3.3	25
198	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020 , 72, 57-66	13.4	25
197	A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 374, 773-6	3.4	24
196	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: A randomized trial. <i>Liver International</i> , 2018 , 38, 636-644	7.9	23
195	JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 8-12	4	23
194	Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1022-6	6.9	23
193	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005 , 13, 175-82	3.5	23
192	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020 , 30, 1144-1153	9.7	23
191	The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 328-34	3.4	22
190	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 406-417	18.8	22
189	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 484-491	4	22
188	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 96-101	6.1	22

187	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 241-248	4	22
186	Improving transient elastography performance for detecting hepatitis B cirrhosis. <i>Digestive and Liver Disease</i> , 2012 , 44, 61-6	3.3	22
185	The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity. <i>PLoS ONE</i> , 2011 , 6, e21856	3.7	22
184	Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 323-9	6.1	22
183	A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 547-555	6.1	21
182	The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. <i>Liver International</i> , 2009 , 29, 25-36	7.9	21
181	Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 681-7	9.7	21
180	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1453-1460.e1	6.9	20
179	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020 , 72, 1230-1241	11.2	20
178	Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 783-9	4	20
177	Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4793-5	9.7	20
176	Treatment of non-alcoholic steatohepatitis with <i>Phyllanthus urinaria</i> : a randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 57-62	4	19
175	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017 , 24 Suppl 2, 25-43	3.4	19
174	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1762-9	4	19
173	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 424-31	6.1	19
172	Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 63-9	4	19
171	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016 , 64, 1507-1517	11.2	19
170	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 145-53	6.1	19

169	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020 , 71, 444-455	11.2	19
168	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019 , 70, 971-981	11.2	18
167	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 461-468.e2	6.9	18
166	Gastrointestinal disease burden and mortality: A public hospital-based study from 2005 to 2014. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 124-131	4	18
165	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014 , 65, 174-86	7.3	18
164	Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 1830-6	9.7	18
163	Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. <i>PLoS ONE</i> , 2015 , 10, e0122406	3.7	18
162	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020 , 4, 8-20	6	18
161	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1213-1224	6.1	17
160	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015 , 9, 43-53	5.8	17
159	Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 3541-7	4	17
158	A magnetic bead-based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. <i>Electrophoresis</i> , 2010 , 31, 1721-30	3.6	17
157	Impact of severe acute respiratory syndrome on liver transplantation service. <i>Transplantation Proceedings</i> , 2004 , 36, 2302-3	1.1	17
156	Retrospective analysis of liver function derangement in severe acute respiratory syndrome. <i>American Journal of Medicine</i> , 2004 , 116, 566-7	2.4	17
155	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3547-3551	0.7	17
154	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1629-1638	0.7	17
153	Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1448-56	4	16
152	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2332-8	5.1	16

151	Individualisation of antiviral therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1206-16	4	16
150	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. <i>Journal of Medical Virology</i> , 2009 , 81, 224-9	19.7	16
149	Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 18, 339-45	6.1	16
148	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018 , 38, 1179-1187	7.9	16
147	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016 , 69, 971-984	7.3	15
146	Aberrant concentrations of liver-derived plasma albumin mRNA in liver pathologies. <i>Clinical Chemistry</i> , 2010 , 56, 82-9	5.5	15
145	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019 , 39, 271-279	7.9	15
144	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 347-352	3	15
143	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1429-1437	3.4	14
142	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1230-1233	4	14
141	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , 2012 , 32, 271-8	7.9	14
140	Chronic hepatitis B: a treatment update. <i>Seminars in Liver Disease</i> , 2013 , 33, 122-9	7.3	14
139	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 972-81	6.1	14
138	Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 1703-11	6.1	14
137	Changing scene in hepatitis B serology interpretation. <i>British Journal of Hospital Medicine</i> , 2002 , 63, 16-9		14
136	Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis. <i>Advances in Therapy</i> , 2016 , 33, 862-75	4.1	14
135	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2020 , 70, 660-666	11.6	13
134	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020 , 50, 1024-1031	5.1	13

133	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020 , 115, 867-875	0.7	13
132	Strategies to manage hepatitis C virus infection disease burden-Volume 4. <i>Journal of Viral Hepatitis</i> , 2017 , 24 Suppl 2, 44-63	3.4	13
131	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 592-8	4	13
130	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, e466-e475	11.6	13
129	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , 2010 , 47, 193-5	14.5	12
128	Treatment of chronic hepatitis B: focus on telbivudine. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 259-68	5.5	12
127	A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 449-58	3.4	12
126	Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 356, 53-9	3.4	12
125	Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004 , 71, 329-33	2.8	12
124	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021 , 74, 1750-1765	11.2	12
123	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 126-135	3.4	12
122	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020 , 69, 1116-1126	19.2	12
121	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon α (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , 2008 , 13, 555-562	1.6	12
120	Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 716-26	6.1	11
119	Antiviral therapy for chronic hepatitis B: challenges in Hong Kong. <i>Journal of Hepatology</i> , 2009 , 51, 1088-94	19.4	11
118	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016 , 62 Suppl 4, S298-305	11.05	11
117	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 582-90	4	10
116	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues. <i>Antiviral Therapy</i> , 2013 , 18, 979-86	1.6	10

115	The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006 , 43, 69-101	9.4	10
114	High incidence of incidental hepatocellular carcinoma exists among hepatic explanted livers. <i>Transplantation Proceedings</i> , 2003 , 35, 350-1	1.1	10
113	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021 , 116, 984-993	0.7	10
112	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 228-235	3.4	9
111	Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?. <i>Antiviral Therapy</i> , 2010 , 15, 607-16	1.6	9
110	A review of telbivudine for the management of chronic hepatitis B virus infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 1351-61	5.5	9
109	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , 2021 ,	13.3	9
108	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. <i>Antiviral Therapy</i> , 2019 , 24, 133-140	1.6	8
107	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2210-2219	4	8
106	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. <i>Hepatology</i> , 2018 , 67, 2302-2319	11.2	8
105	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018 , 38, 1911-1919	7.9	8
104	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. <i>Antiviral Therapy</i> , 2013 , 18, 671-9	1.6	8
103	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2843-2845.e2	6.9	8
102	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1950-1958.e7	6.9	8
101	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020 , 2, 100152	10.3	8
100	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	8
99	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1641-1647	4	7
98	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1509-1517	6.1	7

97	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1969-1979	11.6	7
96	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1190-9	6.1	7
95	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020 , 55, 899-908	6.9	7
94	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 934-941	4	7
93	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019 , 9, 10529	4.9	7
92	Peginterferon therapy for chronic hepatitis B: one size fits all?. <i>Gut</i> , 2013 , 62, 185-7	19.2	7
91	Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Infectious Diseases and Therapy</i> , 2014 , 3, 191-202	6.2	7
90	Revisiting the treatment recommendations for chronic hepatitis B. <i>Hepatology</i> , 2009 , 49, 700; author reply 701-2	11.2	7
89	Fulminant hepatic failure in a patient with inactive HBsAg carrier state, acute hepatitis E and thyrotoxicosis. <i>Hepatology Research</i> , 2003 , 27, 248-251	5.1	7
88	Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis. <i>World Journal of Gastroenterology</i> , 2019 , 25, 4715-4726	5.6	7
87	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1274-1283	0.7	7
86	Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 377-385.e5	6.9	6
85	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 904-914	3.4	6
84	Antiviral drug resistance testing in patients with chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 221-31	4	6
83	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1040-8	4	6
82	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005 , 66, 13-6	0.8	6
81	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. <i>Hepatology Communications</i> , 2021 ,	6	6
80	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2020 , 40, 549-557	7.9	6

79	Improvements in the management of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 1153-1166	4.2	6
78	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1071-1078	4	5
77	Unresolved issues of immune tolerance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020 , 55, 3836-3839	3.9	5
76	hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. <i>Journal of Infectious Diseases</i> , 2020 ,	7	5
75	Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1306-1316	6.1	5
74	Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. <i>Transplantation Proceedings</i> , 2004 , 36, 2287-8	1.1	5
73	ACE inhibitors prevent liver-related events in non-alcoholic fatty liver disease.. <i>Hepatology</i> , 2021 ,	11.2	5
72	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 321-331	6.1	5
71	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1399-1406	6.1	5
70	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , 2020 , 9, 7052-7061	4.8	5
69	HBV variants are common in the immune-tolerant phase of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1061-1070	3.4	4
68	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020 , 20, 128	3	4
67	Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , 2016 , 12, 5-6	14.9	4
66	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1485-93	4	4
65	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011 , 55, 497; author reply 498	13.4	4
64	Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B. <i>American Journal of Medicine</i> , 2003 , 115, 334-6	2.4	4
63	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. <i>Hepatology</i> , 2021 , 73, 1652-1670	11.2	4
62	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00300	4.2	4

61	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00324	4.2	4
60	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018 , 13, e0199198	3.7	4
59	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS). <i>Antiviral Therapy</i> , 2008 , 13, 555-62	1.6	4
58	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 419-20	4	3
57	Do we need a histological score to diagnose non-alcoholic steatohepatitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 494-5; author reply 495-6	6.1	3
56	Reply:. <i>Hepatology</i> , 2009 , 50, 2049-2050	11.2	3
55	Liver transplantation for hepatocellular carcinoma in cirrhotic patients-a single-center experience. <i>Transplantation Proceedings</i> , 2003 , 35, 379-80	1.1	3
54	Complications of liver donation for living related liver transplantation. <i>Transplantation Proceedings</i> , 2004 , 36, 2224-5	1.1	3
53	Complex genetic encoding of the hepatitis B virus on-drug persistence. <i>Scientific Reports</i> , 2020 , 10, 15574.9	4.9	3
52	Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 501-506	4	3
51	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 2202-2209	4	3
50	Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021 , 74, 1795-1808	11.2	3
49	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 260-262	18.8	2
48	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1610-1618	4	2
47	High level virion production and surface antigen expression with 1.5 copies of hepatitis B viral genome. <i>Journal of Virological Methods</i> , 2009 , 159, 135-40	2.6	2
46	Can dietetic intervention for obesity ever succeed in real life?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 459-60	4	2
45	Adoptive immune transfer in liver transplantation of HBV-related liver diseases. <i>Hepatology</i> , 2003 , 37, 1224-5; author reply 1225	11.2	2
44	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2021 ,	6.9	2

43	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021 , 11, 5416	4.9	2
42	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab205	1	2
41	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. <i>Hong Kong Medical Journal</i> , 2021 ,	0.7	2
40	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2021 , 67, 1492-1502	5.5	2
39	Effect of pregnancy on the activity and infectivity of hepatitis B virus in women with chronic hepatitis B infection. <i>Hong Kong Medical Journal</i> , 2015 , 21 Suppl 7, S4-7	0.7	2
38	Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?. <i>Hepatology International</i> , 2013 , 7, 13-5	8.8	1
37	Commentary: how long does one need to fast before a Fibroscan examination?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 540-1	6.1	1
36	Reply: To PMID 24519364. <i>Hepatology</i> , 2014 , 60, 1797-8	11.2	1
35	Letters to the Editors: Potential pitfalls on the validation of liver stiffness measurement by Fibroscan with histological staging in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 937-8	6.1	1
34	Response to Drs. Navaneethan and Jayanthi. <i>American Journal of Gastroenterology</i> , 2007 , 102, 456-456	0.7	1
33	A cirrhotic patient with fever and abdominal pain in the presence of ascites. <i>British Journal of Hospital Medicine</i> , 2003 , 64, 310		1
32	Immunosuppression with rapid steroid reduction among predominantly HBV liver transplantation recipients: initial experience. <i>Transplantation Proceedings</i> , 2003 , 35, 419-20	1.1	1
31	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis.. <i>JHEP Reports</i> , 2022 , 4, 100441	10.3	1
30	Icteric flare of chronic hepatitis B in a 95-year old patient. <i>World Journal of Gastroenterology</i> , 2003 , 9, 2876-7	5.6	1
29	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020 , 92, 1206-1213	19.7	1
28	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021 , 5, 1212-1223	6	1
27	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , 2021 , 41, 182-190	7.3	1
26	Reply. <i>Hepatology</i> , 2016 , 64, 685-6	11.2	1

25	Reply. <i>Gastroenterology</i> , 2016 , 150, 1255	13.3	1
24	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , 2019 , 39, 494-502	7.9	1
23	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021 , 84, 68-73	3.9	1
22	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 616-617	6.1	0
21	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021 , 73, 870	11.2	0
20	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 499-509	6.9	0
19	Reply to: "Serum HBsAg kinetics in clinical prediction". <i>Journal of Hepatology</i> , 2017 , 67, 193-194	13.4	
18	Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter". <i>Journal of Hepatology</i> , 2019 , 70, 1304	13.4	
17	Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma - authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 790	6.1	
16	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , 2020 , 73, 729-730	13.4	
15	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance". <i>Journal of Hepatology</i> , 2017 ,	13.4	
14	Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease--authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1331-2	6.1	
13	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013 , 33, 298-298	7.3	
12	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010 , 59, 277.1-277	19.2	
11	PWE-293 Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general population: randomised controlled trial. <i>Gut</i> , 2012 , 61, A417.1-A417	19.2	
10	Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus-positive donor. <i>Transplantation Proceedings</i> , 2003 , 35, 423-4	1.1	
9	Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B. <i>Transplantation Proceedings</i> , 2004 , 36, 2309-10	1.1	
8	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , 2022 , 2022, 1-13	1	

7	Debate settled for elevated alanine aminotransferase in hepatitis B?. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 750-751	25.5
6	Reply. <i>Hepatology</i> , 2016 , 64, 1820-1821	11.2
5	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 171-2	6.1
4	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021 , 3, 261-269	1
3	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021 , 4, e352	2.2
2	Functional significance of hepatitis B virus subgenotype Cs genomic markers. <i>Hong Kong Medical Journal</i> , 2014 , 20 Suppl 6, 28-30	0.7
1	Non-invasive algorithm for detecting advanced liver fibrosis in chronic hepatitis B patients. <i>Hong Kong Medical Journal</i> , 2014 , 20 Suppl 6, 31	0.7